Enrique R. D. R.
- Country
- Spain
- Department
- Gastroenterology
Research Overview
- Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study of Brenipatide (LY3537031) for Efficacy and Safety in Adults with Irritable Bowel Syndrome‑Constipation
- Efficacy and Safety Evaluation of Saccharomyces boulardii CNCM I-745 in Non-Constipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 3 of 26 partner sites.
Specializations
Gastrointestinal Oncology
The investigator concentrates on colorectal cancer. He also addresses other gastrointestinal malignancies.
- Advanced colorectal carcinoma
- Metastatic gastric adenocarcinoma
- Esophageal squamous cell carcinoma
- Gastroesophageal junction tumors
- Upper gastrointestinal stromal tumors
His work supports novel systemic strategies for solid tumor control.
Hepatobiliary and Pancreatic Therapeutics
He engages in research on hepatocellular carcinoma. Pancreatic adenocarcinoma remains a priority.
- Advanced hepatocellular carcinoma
- Resectable and unresectable pancreatic ductal adenocarcinoma
- Cholangiocarcinoma
- Liver metastasis from colorectal origin
- Combination immunotherapy for liver tumors
Efforts aim to improve survival in liver‑related cancers.
Metabolic and Liver‑Related Disorders
His interests include non‑alcoholic fatty liver disease. Metabolic syndrome linked to liver injury is examined.
- NAFLD progression to fibrosis
- Alpha‑1 antitrypsin deficiency liver disease
- Cirrhosis management
- Lipid disorder‑related atherosclerotic cardiovascular disease
- Liver‑kidney interaction in chronic kidney disease
He explores biomarkers linking metabolism and organ injury.
Inflammatory and Autoimmune Gastrointestinal Conditions
The clinician studies inflammatory bowel disease. Associated immune disorders are also investigated.
- Ulcerative colitis therapeutic optimization
- Crohn’s disease biologic pathways
- Eosinophilic esophagitis
- Celiac disease complications
- Immune‑mediated colitis from checkpoint inhibitors
Research targets disease modulation and quality of life.
Clinical Trial Leadership and Site Expertise
Based at Hospital Clínico San Carlos, he directs multicenter enrollment. Data integrity and patient safety are central.
- Trial coordination across oncology and hepatology
- Regulatory compliance in European studies
- Patient safety monitoring frameworks
- Integration of translational biomarkers
- Training of multidisciplinary research staff
His leadership ensures rigorous execution of therapeutic investigations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.